Tiny study checks heart drug safety in india

NCT ID NCT06086353

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the safety of a drug called Tafamidis (brand name VyndaMx) in 6 people in India with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). In ATTR-CM, faulty proteins build up in the heart and make it harder to pump blood. Researchers tracked side effects for 6 months after patients started taking the drug. The goal was simply to see if the drug is safe in this group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tafamidis (VyndaMx) capsules
What this could lead to: If successful, this study could confirm that Tafamidis is safe for use in Indian patients with ATTR-CM, supporting its continued use.
What could go wrong: This was a very small study (only 6 participants) and only looked at safety, not effectiveness. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

Contacts and locations

Locations

AIG Hospital

Hyderabad, 500032, India
Max Super Speciality Hospital

New Delhi, 110017, India
Sri Jayadeva Institute of Cardiovascular Sciences and Research

Bangalore, Karnataka, 560069, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.